Rxivist logo

Lysyl oxidase inhibition drives the transdifferentiation from lung adenocarcinoma to squamous cell carcinoma in mice

By Shun Yao, Xiangkun Han, Xinyuan Tong, Fuming Li, Zhen Qin, Hsin-Yi Huang, Ji Hongbin

Posted 04 May 2018
bioRxiv DOI: 10.1101/314393

LKB1 is frequently mutated in human non-small cell lung cancer (NSCLC) and Lkb1 deletion in mice triggered the lung adenocarcinoma (ADC) to squamous cell carcinoma (SCC) transdifferentiation (AST) through lysyl oxidase (LOX)-dependent extracellular matrix remodeling. Here we show that pharmacological inhibition of lysyl oxidase in KrasG12D/Trp53L/L mouse model, which is known to produce lung ADC only, triggers the ADC-to-SCC transdifferentiation independent of LKB1 status. Treatments of two different inhibitors of lysyl oxidase decrease collagen deposition and promote redox accumulation, and eventually trigger the AST. Importantly, these transited SCC show strong resistance to lysyl oxidase inhibition in stark contrast to ADC. Collectively, these findings establish a new AST mouse model independent of LKB1 inactivation status.

Download data

  • Downloaded 520 times
  • Download rankings, all-time:
    • Site-wide: 72,403
    • In cancer biology: 2,100
  • Year to date:
    • Site-wide: 58,086
  • Since beginning of last month:
    • Site-wide: 123,798

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide